I lead our Portfolio Strategy group supporting Flatiron's Real World Evidence (RWE) Business Unit. My team is responsible for setting our 4-year business strategies and vision for the development of new RWE solutions (data+services). We evaluate new opportunities in the RWD/E space to provide multi-modal, comprehensive clinical and clinicogenomic data and services across the entire oncology drug development life cycle.

Lead a BD team within our Life Sciences group to provide Real World Data / Evidence to major biopharma partners to support oncology drug development, clinical trial design, and regulatory applications in the US and Globally. Commercial Strategy Lead for Flatiron's Syndicated Retrospective Data (Clinical & Clinico-Genomics Data in partnership with Foundation Medicine).

Former Co-Founder of Dynamic Marching, a music education company creating specialized curricula for music educators at the middle school through collegiate levels. Reached over 10,000 music educators in the US and Japan through our past and present partnerships with Hal Leonard, D'Addario, Wenger, Zildjian, FJ Miller and DSI over the years. Stepped aside at end of 2020 to focus on family.

I managed business development strategy, analytics, and partnership negotiation to match Caris Life Sciences precision medicine genomic profiling lab services, clinical trial candidate patient identification, and biomarker data offerings with pharmaceutical business partnership opportunities. Actively engaged with 15+ pharma relationships on the East Coast and MidwestGenerated over $1M ongoing deal pipeline in <1 yearDeveloped Oncology Clinical Trial lead generation engine across 1800+ oncology trialsSpecialize in Caris's unique biomarker data offerings to support cancer prevalence, HEOR, market access, and drug launch strategies.

I was responsible for the industrialization of a novel and powerful multiplexed high-throughput phenotypic screening technology known as PRISM. By screening tens of thousands of compounds in hundreds of genomically characterized cancer cell lines in parallel, we are able to use drug sensitivity profiles to identify predictive biomarkers and inform mechanism of action, indication selection, and possible patient stratification strategies at the earliest stages of drug discovery.Extensive Alliance Experience: Functioned as main point of contact for multiple US and international biotech and pharma collaborations. Established new seven-figure partnership with a major pharmaceutical client and helped renew seven-figure philanthropic project for novel and repurposed drug discovery.Scientific Strategy and Operational Management: Responsible for external partner scientific and alliance strategy, resulting in a total of $30M+ funding across multiple projects. Established drug screening service model for smaller clients resulting in $1M revenue in first year.Drug Discovery Program Leadership: Established vision, strategy, and operations for novel multiplexed cancer cell line screening drug discovery engine including building a team of 15 people. Rapidly scaled technology with over 90M+ cell line:drug data points generated in 3 years.

Managed multiple research projects and research associate staff toward the development of oligonucleotide functionalized gold nanoparticles or “Spherical Nucleic Acids” (SNA) for therapeutic gene regulation and immunomodulation for oncology, dermatological, and antibacterial applications. Also participated on the development and commercialized team for a live cell mRNA and miRNA detection nanoparticle reagent that tech transferred to Millipore under the SmartFlare brand.

My work focused on the development of oligonucleotide functionalized gold nanoparticles for the detection of miRNA in living cells. Also assisted in projects centered around nano-patterned surfaces using Dip-pen nanolithography for the preferential differentiation of osteoclasts.

Conducted research into the molecular mechanisms of breast cancer metastasis, specifically the role of Abl-family nonreceptor tyrosine kinase-mediated cortactin phosphorylation in the regulation of actin polymerization driven cellular protrusions in human breast cancer. My work demonstrated a novel signalling cascade through EGFR to Src to Arg to cortactin to invadopodia function. Ablation of this cascade blocks invasive properties of breast cancer cells.